|Dr. Geraldine A. Henwood||Pres, CEO & Director||441.06k||N/A||1952|
|Mr. Richard S. Casten CPA, M.B.A.||Chief Financial Officer||N/A||N/A||1974|
|Dr. Stewart McCallum||Chief Medical Officer||N/A||N/A||1966|
|Ms. Diane Myers||Sr. VP of Regulatory & Quality||N/A||N/A||1964|
|Dr. Jyrki Mattila||Exec. VP of Bus. Devel.||N/A||N/A||1955|
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; BX2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and BX3000, an NMBA reversal agent, which is under pre-clinical trial, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine, which is under phase II clinical trial. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
Baudax Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.